Results 101 to 110 of about 27,201 (202)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells [PDF]

, 2008
In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for the treatment of endometrial cancer.
R Finn, Venkatesan, N, Jiang, S-W, D J Slamon, Rahmeh, M, C Ginther, Slamon, DJ, J Dering, Podratz, KC, G Yang, Fejzo, M Schoenberg, Toft, D, Dering, J, G E Konecny, D Toft, Konecny, GE, K C Podratz, N Venkatesan, S-W Jiang, Finn, R, M Schoenberg Fejzo, Yang, G, M Rahmeh, Ginther, C   +23 more
core   +1 more source

Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.

PLoS ONE
The aberrant activation of HER2 has a pivotal role in bone metastasis implantation and progression in several tumor types, including prostate cancer (PC). Trastuzumab and other anti-HER2 therapies, such as lapatinib, have been used in human breast cancer
Carlos Eduardo Fonseca-Alves, Antonio Fernando Leis-Filho, Zara Alves Lacerda, Patricia de Faria Lainetti, Renee Laufer Amorim, Silvia Regina Rogatto   +5 more
doaj   +1 more source

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line

, 2020
Lapatinib, a Human Epidermal growth factor Receptor 2 (HER2)-targeting therapy in HER2-overexpressing breast cancer, has been widely used clinically, but the prognosis is still poor because most patients acquire resistance.
Jeoung-Won Bae, Ki-Cheol Han, Seungho Shin, Yeul Hong Kim, Kyong Hwa Park, Hye Jin Lee, Jinho Kang   +6 more
core   +1 more source

Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

PLoS ONE, 2010
The efficacy of anti-HER2 therapeutics, such as lapatinib and trastuzumab, is limited by primary and acquired resistance. Cellular adaptations that allow breast cancer cell to survive prolonged HER2 inhibition include de-repression of the transcription ...
Alessio Nencioni, Michele Cea, Anna Garuti, Mario Passalacqua, Lizzia Raffaghello, Debora Soncini, Eva Moran, Gabriele Zoppoli, Vito Pistoia, Franco Patrone, Alberto Ballestrero   +10 more
doaj   +1 more source

Lapatinib-Based Radioagents for Application in Nuclear Medicine

Lapatinib is an approved therapeutic agent for the treatment of HER2-positive breast cancer. It has a high affinity for the non-receptor cytoplasmic tyrosine kinases of the EGFR and HER2 receptors. It is a type II inhibitor, with Kiapp values of 3 nM and
Ewa Gniazdowska, Przemysław Koźmiński
core   +1 more source

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

, 2009
Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited and represents a major clinical challenge ...
Greil, R., Oliva, Cristina, Paoletti, Paolo, Zembryki, Denise, Lin, Nancy U, Paul, Devchand, Stemmler, Hans-Joachim, Yardley, Denise, Steplewski, Klaudia, Lossignol, Dominique, Wardley, Andrew, Roychowdhury, Debasish, Blum, J., Loibl, Sibylle, Ciruelos, Eva, Brufsky, Adam, Liu, Cindy Meng Hsin, Dharan, Bernie, Winer, Eric P, Diéras, Véronique, Gori, Stefania, Rubin, Stephen D, Christodoulou, Christos, Roche, Henri   +23 more
core   +1 more source

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer

Cancer Management and Research, 2010
Catherine Oakman, Marta Pestrin, Elena Zafarana, Egidia Cantisani, Angelo Di Leo“Sandro Pitigliani” Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, ItalyAbstract: Lapatinib is a dual
Catherine Oakman, Marta Pestrin, Elena Zafarana, et al   +3 more
doaj  

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

, 2012
HER2 amplification is found in more than 15% of gastric cancers and is associated with poor clinical outcome. Lapatinib, a dual HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has shown promising in vitro results in treating ...
Martin R. Weiser, Chin-Tung Chen, David Liska, Hyaehwan Kim, Sizhi Gao, James G. Christensen   +5 more
core   +1 more source

Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer

, 2010
Purpose Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or epidermal growth factor receptor (EGFR) and human epidermal growth factor ...
Juan J. Zarba, Melissa W. Stutts, Carole Tarpin, Luis Mas Lopez, Ana Oaknin, Jacquelyn A. Alber, Lini N. Pandite, Jie Ding, Wichai Termrungruanglert, Bradley J. Monk   +9 more
core   +1 more source

The concomitant use of lapatinib and paracetamol - the risk of interaction

, 2018
Summary Lapatinib is a tyrosine kinase inhibitor used for the treatment of breast cancer. Paracetamol is an analgesic commonly applied to patients with mild or moderate pain and fever. Cancer patients are polymedicated, which involves high risk
Agnieszka Karbownik, Edmund Grześkowiak, Edyta Szałek, Magdalena Magiera, Zenon J. Kokot, Agnieszka Klupczynska, Szymon Plewa, Katarzyna Sobańska, Tomasz Grabowski, Anna Wolc, Joanna Porażka   +10 more
core   +1 more source